Pathogenesis-based new perspectives of management of ANCA-associated vasculitis.
ANCA-associated vasculitis
Complement
Rituximab
Journal
Autoimmunity reviews
ISSN: 1873-0183
Titre abrégé: Autoimmun Rev
Pays: Netherlands
ID NLM: 101128967
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
05
12
2021
accepted:
25
12
2021
pubmed:
1
1
2022
medline:
23
2
2022
entrez:
31
12
2021
Statut:
ppublish
Résumé
While the pathogenesis of anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV) is still not fully elucidated, there is a mounting evidence that the process is initiated by inflammation and activation of innate immunity in the presence of predisposing factors, innate immunity abnormalities, aberrant responses of the adaptive immune system, and complement system activation. Biologics targeting inflammation-related molecules in the immune system have been explored to treat AVV, and these treatments have provided revolutionary advances. When focusing on the pathogenic mechanisms of AVV, this review presents the new findings regarding novel therapeutic approaches for the management of these conditions.
Identifiants
pubmed: 34971805
pii: S1568-9972(21)00312-8
doi: 10.1016/j.autrev.2021.103030
pii:
doi:
Substances chimiques
Antibodies, Antineutrophil Cytoplasmic
0
Biological Products
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103030Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.